Immunome annual debt-to-equity ratio
2020
2022
2023
2024
2025
Immunome Debt-to-Equity Ratio Growth & History (IMNM)
Immunome's debt-to-equity ratio was 0.01 for fiscal 2025.
View full Immunome company overviewImmunome annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.01 | −0.02 | −77.22% |
| 2024 | 2024-12-31 | 0.03 | 0.01 | +93.79% |
| 2023 | 2023-12-31 | 0.01 | −0.00 | −21.24% |
| 2022 | 2022-12-31 | 0.02 | — | — |
| 2020 | 2020-12-31 | 0.01 | — | — |
Immunome quarterly debt-to-equity ratio
Q4.20
Q1.21
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.01 | −0.01 | −41.31% |
| Q1 2026 | 2026-03-31 | 0.01 | −0.01 | −59.60% |
| Q4 2025 | 2025-12-31 | 0.01 | −0.02 | −77.22% |
| Q3 2025 | 2025-09-30 | 0.02 | 0.00 | +20.09% |
| Q2 2025 | 2025-06-30 | 0.02 | 0.00 | +40.86% |
| Q1 2025 | 2025-03-31 | 0.02 | 0.01 | +267.76% |
| Q4 2024 | 2024-12-31 | 0.03 | 0.01 | +93.79% |
| Q3 2024 | 2024-09-30 | 0.01 | — | — |
| Q2 2024 | 2024-06-30 | 0.01 | — | — |
| Q1 2024 | 2024-03-31 | 0.00 | — | — |
| Q4 2023 | 2023-12-31 | 0.01 | — | — |
| Q1 2021 | 2021-03-31 | 0.01 | — | — |
| Q4 2020 | 2020-12-31 | 0.01 | — | — |
Immunome debt-to-equity ratio trends
Over the last five fiscal years, Immunome's debt-to-equity ratio decreased from 0.01 to 0.01, a change of −0.01. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗